We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)
References
GreenD, LechnerK. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII.Thromb Haemost1981; 45: 200–203.Google Scholar
SallahS. Inhibitors to clotting factors.Ann Hematol1997; 75: 1–7.Google Scholar
NegrierC, GoudemandJ, SultanY, BertrandM, RothschildC, LaurouaP. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity.Thromb Haemost1997; 77: 1113–1119.Google Scholar
HayCR, NegrierC, LudlamCA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study.Thromb Haemost1997; 78: 1463–1467.Google Scholar
TurecekPL, VaradiK, GritschH, et al. Factor Xa and prothrombin: mechanism of action of FEIBA.Vox Sang1999; 77(Suppl. 1): 72–79.Google Scholar